Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA priority review
Biotech
Stealth CEO questions FDA rejection of rare disease drug
“We are kind of hanging on by our fingernails here to try to bring this drug to the patient community,” Stealth CEO Reenie McCarthy told Fierce Biotech.
Gabrielle Masson
May 29, 2025 2:27pm
Vertex meets own cystic fibrosis record with next-gen treatment
Feb 5, 2024 7:50pm
FDA gives Madrigal's NASH drug priority review, no AdComm
Sep 13, 2023 10:50am
Biogen's tight-lipped zuranolone remarks disquiet Sage investors
Jul 26, 2023 10:45am
Pfizer's maternal RSV vaccine filing sets up AZ, Sanofi showdown
Feb 21, 2023 9:15am
Pfizer's RSV vaccine rush gets FDA boost with priority review
Dec 7, 2022 10:10am
